Stock Price Prediction

PULM stock closed at $7.70 on January 31, 2025, with a slight gain of +0.39%. Bulls may view the stock positively due to its recent cross-license agreement with MannKind, which could enhance its product pipeline and operational efficiency. However, the $95M mixed shelf offering may dilute shares, limiting immediate upside potential.

Pulmatrix (PULM) faces bearish sentiment due to its weak financial performance, including a Q2 2024 EPS of -$1.59 and revenue of only $1.55M, reflecting poor profitability and growth potential. The recent $95M mixed shelf offering signals potential dilution, further pressuring the stock price. Additionally, operational restructuring, such as the lease transfer to MannKind, suggests financial strain rather than growth, making the stock unattractive for now.